MNMD
Price
$9.72
Change
-$0.25 (-2.51%)
Updated
Aug 14 closing price
Capitalization
739.57M
89 days until earnings call
ZVRA
Price
$8.90
Change
-$0.53 (-5.62%)
Updated
Aug 14 closing price
Capitalization
490.25M
82 days until earnings call
Interact to see
Advertisement

MNMD vs ZVRA

Header iconMNMD vs ZVRA Comparison
Open Charts MNMD vs ZVRABanner chart's image
Mind Medicine (MindMed)
Price$9.72
Change-$0.25 (-2.51%)
Volume$884.5K
Capitalization739.57M
Zevra Therapeutics
Price$8.90
Change-$0.53 (-5.62%)
Volume$3.39M
Capitalization490.25M
MNMD vs ZVRA Comparison Chart in %
Loading...
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
MNMD vs. ZVRA commentary
Aug 15, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is MNMD is a Hold and ZVRA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Aug 15, 2025
Stock price -- (MNMD: $9.72 vs. ZVRA: $8.90)
Brand notoriety: MNMD and ZVRA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: MNMD: 71% vs. ZVRA: 277%
Market capitalization -- MNMD: $739.57M vs. ZVRA: $490.25M
MNMD [@Biotechnology] is valued at $739.57M. ZVRA’s [@Biotechnology] market capitalization is $490.25M. The market cap for tickers in the [@Biotechnology] industry ranges from $100.07B to $0. The average market capitalization across the [@Biotechnology] industry is $1.86B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

MNMD’s FA Score shows that 0 FA rating(s) are green whileZVRA’s FA Score has 1 green FA rating(s).

  • MNMD’s FA Score: 0 green, 5 red.
  • ZVRA’s FA Score: 1 green, 4 red.
According to our system of comparison, MNMD is a better buy in the long-term than ZVRA.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

MNMD’s TA Score shows that 4 TA indicator(s) are bullish while ZVRA’s TA Score has 4 bullish TA indicator(s).

  • MNMD’s TA Score: 4 bullish, 5 bearish.
  • ZVRA’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both MNMD and ZVRA are a bad buy in the short-term.

Price Growth

MNMD (@Biotechnology) experienced а -2.70% price change this week, while ZVRA (@Biotechnology) price change was -26.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.69%. For the same industry, the average monthly price growth was +27.47%, and the average quarterly price growth was +19.86%.

Reported Earning Dates

MNMD is expected to report earnings on Nov 12, 2025.

ZVRA is expected to report earnings on Nov 05, 2025.

Industries' Descriptions

@Biotechnology (+7.69% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
MNMD($740M) has a higher market cap than ZVRA($490M). MNMD YTD gains are higher at: 39.655 vs. ZVRA (6.715). ZVRA has higher annual earnings (EBITDA): -60.3M vs. MNMD (-110.19M). MNMD has more cash in the bank: 183M vs. ZVRA (62.6M). MNMD has less debt than ZVRA: MNMD (41.2M) vs ZVRA (61.8M). ZVRA has higher revenues than MNMD: ZVRA (40.6M) vs MNMD (0).
MNMDZVRAMNMD / ZVRA
Capitalization740M490M151%
EBITDA-110.19M-60.3M183%
Gain YTD39.6556.715591%
P/E RatioN/AN/A-
Revenue040.6M-
Total Cash183M62.6M292%
Total Debt41.2M61.8M67%
FUNDAMENTALS RATINGS
MNMD vs ZVRA: Fundamental Ratings
MNMD
ZVRA
OUTLOOK RATING
1..100
74
VALUATION
overvalued / fair valued / undervalued
1..100
41
Fair valued
80
Overvalued
PROFIT vs RISK RATING
1..100
9278
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
3958
P/E GROWTH RATING
1..100
10026
SEASONALITY SCORE
1..100
3724

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

MNMD's Valuation (41) in the null industry is somewhat better than the same rating for ZVRA (80). This means that MNMD’s stock grew somewhat faster than ZVRA’s over the last 12 months.

ZVRA's Profit vs Risk Rating (78) in the null industry is in the same range as MNMD (92). This means that ZVRA’s stock grew similarly to MNMD’s over the last 12 months.

MNMD's SMR Rating (97) in the null industry is in the same range as ZVRA (100). This means that MNMD’s stock grew similarly to ZVRA’s over the last 12 months.

MNMD's Price Growth Rating (39) in the null industry is in the same range as ZVRA (58). This means that MNMD’s stock grew similarly to ZVRA’s over the last 12 months.

ZVRA's P/E Growth Rating (26) in the null industry is significantly better than the same rating for MNMD (100). This means that ZVRA’s stock grew significantly faster than MNMD’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
MNMDZVRA
RSI
ODDS (%)
Bearish Trend 1 day ago
87%
Bullish Trend 1 day ago
88%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
80%
Bearish Trend 1 day ago
78%
Momentum
ODDS (%)
Bullish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
MACD
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
83%
TrendWeek
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
79%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
85%
Bearish Trend 1 day ago
77%
Advances
ODDS (%)
Bullish Trend 4 days ago
84%
Bullish Trend 9 days ago
81%
Declines
ODDS (%)
Bearish Trend 1 day ago
85%
Bearish Trend 1 day ago
77%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
Bullish Trend 1 day ago
83%
Aroon
ODDS (%)
Bullish Trend 1 day ago
81%
Bullish Trend 5 days ago
83%
View a ticker or compare two or three
Interact to see
Advertisement
MNMD
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
ZVRA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
MMMPX25.33N/A
N/A
Morgan Stanley Inst Emerging Mkts R6
GLVNX81.77N/A
N/A
Invesco Global Focus R
NEQIX13.12N/A
N/A
Neuberger Berman U.S. Equity Impact I
NWKCX84.00N/A
N/A
Nationwide Geneva Small Cap Gr R6
DEMZX26.51N/A
N/A
Macquarie Emerging Markets R6

MNMD and

Correlation & Price change

A.I.dvisor indicates that over the last year, MNMD has been loosely correlated with RXRX. These tickers have moved in lockstep 51% of the time. This A.I.-generated data suggests there is some statistical probability that if MNMD jumps, then RXRX could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To MNMD
1D Price
Change %
MNMD100%
-2.51%
RXRX - MNMD
51%
Loosely correlated
-1.05%
ATAI - MNMD
50%
Loosely correlated
-0.99%
EYPT - MNMD
50%
Loosely correlated
-1.45%
OCUL - MNMD
49%
Loosely correlated
+1.20%
BEAM - MNMD
48%
Loosely correlated
+0.63%
More

ZVRA and

Correlation & Price change

A.I.dvisor indicates that over the last year, ZVRA has been loosely correlated with ATXS. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if ZVRA jumps, then ATXS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ZVRA
1D Price
Change %
ZVRA100%
-5.62%
ATXS - ZVRA
34%
Loosely correlated
-1.60%
CLDX - ZVRA
34%
Loosely correlated
-0.20%
MNMD - ZVRA
34%
Loosely correlated
-2.51%
COGT - ZVRA
33%
Loosely correlated
-2.25%
AXON - ZVRA
33%
Loosely correlated
-2.05%
More